|  |  |
| --- | --- |
|  | PROGRAM/SPEAKER INFORMATION FORMNote: this form is optional if the information is submitted elsewhere. |
| *Program Number:*  |
| *Program Title:* *The Role of Lactate in the Risk Assessment of Morbidity and Mortality* |
| *Date: Contact Hours: 1.0**Location:*  |
| *P.A.C.E.® Provider:**Lecture with slides* |
| *Format: (Lecture, slides, discussion group, live webinar, archived webinar, Computer-Driven Instruction, etc.)**Jim Aguanno, PhD Senior Clinical Consultant Siemens Healthineers* |
| *Speaker Name, Credentials, and Affiliation: List your name and credentials, as they should appear in the program. \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_* |
| *List your professional affiliation, as it should appear in the program:* |
| *The moderator or speaker will disclose to the audience any conflict of interest regarding the topic being presented.*  |
| *­Description of Session: Limit to 50 words. Type or print, being as specific as possible about learning to take place.**The value of measuring lactate levels is expanding. Though generally considered a nonspecific biomarker, knowing lactate levels early in a patient’s presentation can provide valuable information to help guide assessment and treatment. It can be particularly useful in ICU and ED settings where the presentation of symptoms may be inconclusive while diseases progress rapidly with severe pathology. Lactate testing can open a critical window for early intervention when treatment is most likely to be successful.* *This seminar provides a framework for understanding lactate and the role it can play as a prognostic indicator of morbidity and mortality. The recently amended changes to the definition of sepsis and the role of lactate will also be discussed.* |
| *Level of Instruction:* ***BASIC INTERMEDIATE ADVANCED*** *(Circle one)****BASIC:*** *Entry level; no prior knowledge of subject necessary to attend this program;* ***INTERMEDIATE:*** *Refresher course; some basic knowledge required;* ***ADVANCED:*** *Highly technical; for those with at least five years of experience in a specialty area.**PROGRAM OBJECTIVES (Please list three. May be continued with an attachment)**At the end of the session, the participant will be able to:* |
| 1. Understand the role of lactate as a prognostic indicator for morbidity and mortality
2. Identify disease states where lactate testing can add significant clinical value.
3. Understand the new definition of sepsis and the role of lactate in that definition.
4. Understand the urgency associated with assessing lactate levels.
 |
| *PROGRAM TIME TABLE* |
| *Begin time\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ End time\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_*  |
| *Break(s)\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ Lunch\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_*  |
| *CONTACT HOURS PROPOSED: \_\_\_\_1.0\_\_\_* | *CONTACT HOURS: \_\_\_\_\_\_\_\_ per Committee (for Office Use Only)* |

|  |  |
| --- | --- |
|  | Professional Acknowledgment for Continuing EducationSPEAKER INFORMATION FORM Not all blanks need to be completed. |

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|

|  |
| --- |
| Name:Jim Aguanno, PhD |
| Current Position:Senior Clinical Consultant, Siemens Healthineers |
| Business Address:511 Benedict Ave |
| City, State, Zip:Tarrytown, NY |
| Phone: Fax: Email:972-567-7777 james.aguanno@siemens-healthineers.com |
| Area of expertise:Laboratory Medicine |
| Credentials:PhD in Biochemistry; Core Lab Director for 24 years |
| Certifications/Agency: |
| Relevant Experience pertaining to the topic to be presented (papers, presentations, publications):Director of the Core Laboratory and the Head of POCT at Baylor University Medical Center in Dallas, TX |
| Information for a Program Introduction:Dr. Aguanno received a Ph.D. in Biochemistry from Memphis State University. Following his Ph.D., he did two post-doctoral fellowships one at the University of Pittsburgh School of Medicine and a second in Laboratory Medicine at Washington University School of Medicine and Barnes Hospital in St. Louis, Missouri. Dr. Aguanno was Director of the Core Laboratory at Baylor University Medical Center in Dallas, Texas for 24 years. Dr. Aguanno joined Siemens Healthcare Diagnostics in January of 2004 and is currently Senior Clinical Specialist in the Disease State Management group and provides educational presentation on a variety of clinical topics. |

 |

\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_